RxDoctor Payments Data

Jennifer Harrison

Critical Care Medicine · Anniston, ALNPI 1497397558

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Johnson & Johnson at 24.8% of the total. Reporting peaked in 2021 at $500 and has fallen 72.8% since, to $136 in 2025.

$1,409in general payments, 2019–2025

Across 74 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$349
  • E.r. Squibb & Sons, L.L.C.$260
  • Merck$225
  • Abiomed$143
  • Solventum Corporation$121
  • AstraZeneca$80
  • plus $230 from 8 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,409 in reported general payments places this provider in the 70th percentile of 73 critical care medicine providers in Alabama.

See all critical care medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$3,198
Medicare patients
26
Services billed
43

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$42,506
Atorvastatin Calcium73$638
Isosorbide Mononitrate ErIsosorbide Mononitrate24$619
Losartan Potassium28$403
ClopidogrelClopidogrel Bisulfate46$373
Amiodarone Hcl18$365
Amlodipine Besylate51$351
Metoprolol Succinate26$273
Potassium Chloride33$244
Metoprolol Tartrate54$204
Atenolol20$197
Tamsulosin Hcl11$181
Methocarbamol32$143
Carvedilol28$135
Lisinopril19$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$53$42,50656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 73 critical care medicine providers in Alabama.

Other critical care medicine in Anniston

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →